Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two antibiotic cocktails face off to wipe out stomach bacteria

NCT ID NCT07810985

Cure Sponsor: Reham Abdelkader Elkhouly Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

Researchers compare two 14-day oral antibiotic regimens for eradicating Helicobacter pylori, the bacterium behind most stomach ulcers. One regimen combines bismuth, doxycycline, metronidazole, and esomeprazole; the other adds bismuth to clarithromycin, amoxicillin, and esomeprazole. The trial enrolls 200 adults with confirmed H. pylori who have not been treated before. It measures cure rates and tracks side effects and treatment compliance in both groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Two 14-day antibiotic combinations: bismuth quadruple therapy and bismuth added to clarithromycin triple therapy
What this could lead to
If one regimen clears H. pylori more reliably, it could become a preferred first-line treatment for the infection that causes most stomach ulcers.
What could go wrong
Antibiotic resistance and side effects like nausea or diarrhea can lower cure rates or make people stop treatment early. Results from 200 people may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

200 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥ 18 years. * Confirmed diagnosis of H. pylori infection. Exclusion Criteria: * Pregnant or lactating women. * Prior treatment for H. pylori infection. * History of antibiotic or PPI use within the month preceding enrollment. * History of hypersensitivity or allergic reaction to any of the study drugs. * Presence of any contraindication to the study medications. * Advanced chronic liver disease or renal disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eradication of helicobacter pylori are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eradication of helicobacter pylori Helicobacter eradication

Contacts and locations

Locations

  • Tanta university

    Tanta, Algharbia, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.